ACM
BMRN icon

Aubrey Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aubrey Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,500
Closed -$424K – 46
2026
Q1 		$424K Sell
7,500
-5,380
-42% -$314K 0.23% 43
2025
Q4 		$760K Buy
12,880
+2,780
+28% +$151K 0.3% 46
2025
Q3 		$546K Buy
+10,100
New +$578K 0.17% 45

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Aubrey Capital Management's BMRN Position: Q2 2026 in Review

Aubrey Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 7,500 shares — an estimated $424K sold.

Aubrey Capital Management first reported a position in BMRN in Q3 2025 and held it in 3 quarters. The position peaked at $760K in Q4 2025. 178 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Aubrey Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Aubrey Capital Management sold 7,500 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $424K.
  • Aubrey Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Aubrey Capital Management's BioMarin Pharmaceuticals position peaked at $760K in Q4 2025.
  • 178 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Aubrey Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.